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Abstract
Background: Parasite-specific IgE levels correlate with human resistance to reinfection with
Schistosoma spp. after chemotherapy. Although the role of eosinophils in schistosomiasis has been
the focus of a great deal of important research, the involvement of other Fcε receptor-bearing cells,
such as mast cells and basophils, has not been investigated in relation to human immunity to
schistosomes. Chemotherapy with praziquantel (PZQ) kills schistosomes living in an in vivo blood
environment rich in IgE, eosinophils and basophils. This releases parasite Ags that have the potential
to cross-link cell-bound IgE. However, systemic hypersensitivity reactions are not induced by
treatment. Here, we describe the effects of schistosomiasis, and its treatment, on human basophil
function by following changes in total cellular histamine and in vitro histamine-release induced by
schistosome Ags or anti-IgE, in blood samples from infected Ugandan fishermen, who are
continuously exposed to S. mansoni infection, before and 1-day and 21-days after PZQ treatment.
Results: There was a significant increase in the total cellular histamine in blood samples at 1-day
post-treatment, followed by a very significant further increase by 21-days post-treatment. In vitro
histamine-release induced by S. mansoni egg (SEA) or worm (SWA) Ags or anti-IgE antibody, was
significantly reduced 1-day post-treatment. The degree of this reduction correlated with pre-
treatment infection intensity. Twenty-1-days post-treatment, SEA-induced histamine-release was
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BMC Immunology 2004, 5 http://www.biomedcentral.com/1471-2172/5/6still significantly lower than at pretreatment. Histamine-release was not correlated to plasma
concentrations of total or parasite-specific IgE, nor to specific IgG4 plasma concentrations.
Conclusion: The biology of human blood basophils is modulated by S. mansoni infection and
praziquantel treatment. Infection intensity-dependent suppression of basophil histamine-release,
histamine-dependent resistance to infection, and similarities with allergen desensitisation are
discussed as possible explanations of these observations.
Background
High levels of circulating IgE are characteristic of both par-
asitic helminth infections and hypersensitivity conditions
such as asthma and allergy. IgE and other Th2 mediated
responses have been shown to be important in immunity
to helminth infections. In human populations living in
schistosomiasis endemic areas, high levels of IL-4, IL-5
[1,2], eosinophilia [3] and parasite-specific IgE are associ-
ated with resistance to reinfection after chemotherapy [4-
6]. In previous studies in Kenya, levels of IgE specific for
the adult Schistosoma mansoni worm, when measured after
PZQ treatment but before re-infection, negatively corre-
lated with subsequent reinfection intensities [7]. Specific
IgE responses against Ags present in the outer tegument of
the adult worm were also significantly associated with
resistance to reinfection after treatment [8]. Human IgE
and eosinophils have been shown to combine in anti-
body-dependent, cellular cytotoxicity mechanisms
(ADCC) to kill early schistosome larvae in vitro[9]. How-
ever, this mechanism may not be as effective in vivo as, on
penetration of its vertebrate host, the parasite rapidly dis-
guises its outer tegumental surface by absorbing host Ag
[10] and also becomes innately refractory to ADCC killing
[11]. The roles of other major Fcε receptor-bearing effector
cells such as mast cells and basophils has yet to be defined
in human immunity to schistosomiasis. In vitro basophil
studies have suggested a secretagogue potential of some S.
mansoni Ag [12,13] or of plasma factors from infected
patients [13], but the relationship between S. mansoni
infection and basophils, and its relationship with human
susceptibility to infection/reinfection, is not known. The
role of basophils in allergy is an active area of research.
Interestingly, it is suggested that allergic diseases are less
prevalent in areas that are endemic for helminth infec-
tions and, when they are present, the manifestations of
these diseases are less severe in helminth-infected individ-
uals [14]. Various immune regulatory processes have been
put forward as candidate mechanisms for the control of
the potentially adverse effects of IgE responses in connec-
tion to both potential hypersensitivity to helminth Ags
themselves and allergy in general [15].
Chemotherapy to kill schistosome worms whilst they are
living in an intravenous environment that is rich in IgE,
eosinophils and basophils, would seem to have the poten-
tial to induce a systemic hypersensitivity reaction. Orally
administered PZQ, the drug of choice, is rapidly absorbed
into the blood, where it can be metabolised within 90
minute[16]. Within one hour of contact with PZQ, the
outer tegument of the worm is severely disrupted [17].
This rapid disruption of the worm tegument would lead to
the exposure of worm Ags, some known to be recognised
by IgE [7], directly to the blood. Despite this, only a very
few heavily infected older individuals have transient
hypersensitivity responses, usually within a few hours of
treatment, such as urticaria and oedema[18]. This suggests
that some aspect(s) of infection or reactions between
infection and host response to infection, circumvents the
most potentially damaging effects of systemic interactions
between specific-IgE, mass-released parasite Ags and
immune effector cells such as mast cells, eosinophils and
basophils.
Here we describe the effects of schistosomiasis and the
intravenous killing of the parasite on basophil function by
following the changes in total cellular histamine content
and in vitro basophil histamine-release induced by schis-
tosome Ags or anti-IgE Ab. The studies were carried out
using washed blood from infected Ugandan fishermen,
before and at 1-day and 21-days after they were treated
with PZQ.
Results and discussion
Increases in total cellular histamine content of blood in S. 
mansoni infected individuals 1-day and 21-days after 
treatment
Washed blood, as defined in the Methods, was used to
determine the total cellular histamine content of S. man-
soni-infected individuals. By using total cellular hista-
mine, rather than basophil number, we were able to
compare the amount of histamine released with different
stimuli with the amount of cellular histamine available in
the blood at each of the times of sampling, irrespective of
basophil number and degree of basophil activation. As
most platelets are believed to be depleted during the
washing steps and as basophils are the major contributor
to blood cellular histamine, the most significant meas-
ured histamine was of basophil origin. Figure 1 shows
that, between pre-treatment and 1-day post-treatment,
there was a significant increase in total cellular histamine
content of the blood of infected individuals (P = 0.019, n
= 25), and a very significant increase by 21-days post-treat-Page 2 of 12
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between 1-day and 21-days post-treatment time points (p
= 0.005, n = 25). Total cellular histamine content was also
measured in the washed whole blood cells from eight
individuals who had not been exposed to schistosomiasis
at the same time as the 21-days post-treatment samples
were processed. Values of median cellular histamine con-
tent for the infected study cohort at the three time-points
and for the non-exposed group are summarised in Table
1. This shows that the median histamine content in the
non-exposed group was close to the increased median his-
tamine content found in the blood from the S. mansoni-
infected group 21-days post-treatment. The non-exposed
donors were not matched for age and sex with the infected
cohort (and therefore are not considered as a control
group), however, it is possible that the observed augmen-
tation of total histamine after treatment may represent a
return to a normal, uninfected, steady state rather than a
treatment-related up-regulation. A classical interpretation
of these observations would be that infected individuals
have lowered basophil counts and after treatment their
basophil counts return to levels comparable to those
found in non-infected individuals. Alternatively, the low
total cellular histamine content could be attributable to
lowered histamine content per cell.
Changes in maximal histamine-release from the blood of 
S. mansoni-infected individuals 1-day after treatment
The maximal level of histamine released when washed
whole blood cells were cultured in the presence of either
anti-IgE Ab, or SEA or SWA schistosome Ag is shown in
Table 2. It is expressed either as a percentage of total cellu-
lar histamine released, and thereafter called histamine-
releasability, or as the absolute amount of released hista-
mine in ng/ml. Histamine-releasability data reflect how
much of the total cellular histamine present in a standard
volume of blood can be released in response to either
anti-IgE Ab or schistosome Ag. The absolute amount of
released histamine reflects how much histamine a partic-
ular stimulant could release from cells in a standard vol-
ume of blood, whether this is a function of basophil
numbers and/or their histamine-releasability state. Poten-
tial spontaneous release was subtracted from the final
assay value during histamine measurement, thus only
stimuli effects were measured.
Figure 2 shows that before treatment, the basophils of
most infected individuals were able to release histamine
via an IgE-dependent pathway and after SEA or SWA stim-
ulation. Basophils from individuals that had not been
exposed to schistosomiasis showed no significant release
upon stimulation with SEA or SWA used at the same con-
centrations under the same conditions (data not shown).
Circulating specific and non-specific IgE is greatly elevated
in chronically infected schistosomiasis patients [19,20]
Increases in total cellular histamine content of blood from S. mansoni-infected individuals pre-tr atment, 1- and 21-dayspost-tr atmenFigure 1
Increases in total cellular histamine content of blood 
from S. mansoni-infected individuals pre-treatment, 
1- and 21-days post-treatment. The changes in total cel-
lular histamine content (ng/ml) from washed blood of S. man-
soni-infected individuals (n = 25) from pre-treatment levels to 
1-day (black square) or 21-days (open square) after treat-
ment with praziquantel. Any point that plots on the diagonal 
line is unchanged from the pre-treatment level. The differ-
ences in the levels of total cellular histamine were statistically 
significant between all time points and increased pre-treat-
ment<1-day post-treatment<21-days post-treatment.
Table 1: Total cellular histamine content in the blood of S. 
mansoni-infected individuals, pre- and post-treatment, and in non 
infected individuals.
Median total cellular histamine 
content (ng/ml)
pre-treatment (N = 32) 81.0 (43.5 – 97.0)
1 day post treatment (N = 29) 108.0 (85.5 – 145.5)
21 days post-treatment (N = 25) 160.5 (83.8 – 278.8)
non-infected (N = 8) 179.0 (163.0 – 248.5)
Median total cellular histamine content, expressed as ng/ml blood, 
from S. mansoni-infected individuals, and from non-infected individuals. 
Total cellular histamine content was measured in whole washed blood 
of each S. mansoni-infected individuals at pre-treatment, 1-day or 21-
days post-treatment, and in each non-infected individuals at the same 
time as 21-days post-treatment. Numbers in brackets are 25% and 
75% percentiles, respectively.Page 3 of 12
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measured in the plasma of S. mansoni-infected individuals
at pretreatment, 1-day and 21-days post-treatment was
587.5 UI (range 2603), 404.1 UI (range 2276.7) and
1616.5 UI (range 2850.4), respectively. The values are in
the same range as previously reported in S. mansoni-
infected patients [20,21] and are comparable to what has
been reported in highly allergic individuals[22]. Noticea-
bly, a rise in total IgE for a few months after the release of
antigens in the blood has also been reported in allergic
patients after desensitisation, but total IgE decreased in
the longer term [23]. Our study did not include time-
points later than 21-days post-treatment but an elevation
of serum total IgE has been reported 4 months after an
anti-schistosomiasis treatment [21]. As might be expected,
non-Ag-specific anti-IgE stimulation induces histamine-
release from the basophils from the study cohort. As
shown in Figure 3, anti-SEA and anti-SWA IgE was
detected in the plasma of the study participants at all time
points and would, therefore, have been able to occupy
basophil FcεR1.
At 1-day post-treatment, most individuals showed
decreased histamine-releasability (Figure 2). Histamine-
releasability induced by SEA (p = 0.002, n = 21); SWA (p
= 0.004, n = 23); and anti-IgE (p = 0.001, n = 23) dropped
very significantly, as did the absolute amount of released
histamine (Table 2). This reduced ability to release cellu-
lar histamine, including after anti-IgE stimulation, sug-
gests a general desensitisation, similar to that reported in
the desensitization of individuals to specific allergens by
either sub-optimal or super-optimal IgE receptor activa-
tion [24-26]. Praziquantel is a short acting drug that
quickly causes the release of Ags from damaged worms
and eggs. This may result in a rapid, in vivo basophil
degranulation that desensitises the basophils to further Ag
stimulation. Since total cellular histamine is low, the
extent of such an early release would be limited, as shown
in Table 2 by the absolute amount of released histamine
lower at pre-treatment than at 21 days post-treatment,
thus preventing the onset of hypersensitivity reactions
after treatment. Additionally, any such early in vivo release
of histamine may down-regulate further release through
an autocrine mechanism involving H2 receptors [27].
A alternative explanation of this down-regulated hista-
mine-releasability, in the presence of increased cellular
histamine content, may be that after the worms and eggs
destruction and subsequent release of parasite Ags by
Praziquantel treatment, immature bone marrow
basophils were freshly released into the blood. This mech-
anism has been suggested as the cause of increased
basophil counts associated with reduced histamine-
release in allergic patients 5 days after treatment with rhG-
CSF [28].
Changes in maximal histamine release from the blood of S. 
mansoni-infected individuals 21-days after treatment
At 21-days post-treatment, SEA or anti-IgE stimulated his-
tamine-releasability by the blood of most patients was
still significantly lower than it was before treatment (Fig-
ure 2; SEA: p = 0.017, anti-IgE: p = 0.059). Thus, it
appeared that the blood basophils were desensitized 1-
day post-treatment and that, in relation to anti-IgE and
SEA at least, this desensitised state was still evident 21-
days after treatment. However, the absolute amount of
released histamine was significantly higher at 21-days
post-treatment compared with pre-treatment levels with
SEA (p = 0.009), SWA (p = 0.000) or anti-IgE Ab (p =
0.008) stimulation (Figure 2 and Table 2). At 21-days
post-treatment, histamine-releasability was not higher
than pre-treatment % histamine-releasability, suggesting
Table 2: Histamine released from the blood of S. mansoni-infected individuals, pre- and post-treatment, after in vitro stimulation with 
anti-IgE or schistosome Ag.
anti-IgE SEA SWA
ng/ml % ng/ml % ng/ml %
pre-treatment 
(N = 32)
24.3 (20.5;38.0) 35.0 (22.6;51.8) 32.8 (23.4;44.5) 49.7 (26.9;61.6) 31.5 (23.9;44.1) 51.3 (21.5;66.9)
1-day post-treatment 
(N = 29)
16.5 (9.8, 26.0) 14.5 (7.5;28.5) 20.0 (9.0;36.0) 19.1 (8.0;38.1) 20.0 (9.8;31.0) 17.1 (8.2;37.8)
21-days post-treatment 
(N = 25)
35.5 (22.8;51.0) 20.5 (15.2;31.3) 37.5 (29.0;63.3) 25.7 (15.5;39.9) 48.0 (37.0;68.3) 33.2 (21.7;44.6)
Median histamine-release, expressed as absolute amount (ng/ml blood) or as histamine-releasability (% of total cellular histamine content of the 
blood) from each S. mansoni-infected individual, induced by in vitro stimulation with either anti-IgE, SEA or SWA, pre-treatment, 1-day or 21-days 
post-treatment. Numbers in brackets are 25% and 75% percentiles, respectively. Differences in absolute amounts between pre-treatment and 
either post-treatment time-points are statistically significant (p < 0.05). Differences in absolute amounts between SEA-stimulated and anti-IgE-
stimulated histamine-release and between SWA-stimulated and anti-IgE-stimulated histamine-release are statistically significant (p < 0.05) at all time-
points. The difference in absolute amounts between SEA-stimulated and SWA-stimulated histamine-release is statistically significant(p < 0.05) at 21-
days post-treatment. Statistically significant differences in histamine-releasability are mentioned in the text. (Wilcoxon's ranks tests).Page 4 of 12
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The percentage of histamine released from the blood 
of S. mansoni-infected individuals, pre- and post-treat-
ment, after in vitro stimulation with anti-IgE or schis-
tosome Ag. Histamine-releasability (the maximum level of 
histamine-release, expressed as the % of total cellular hista-
mine content of the blood of each individual), from the 
washed blood cells of S. mansoni-infected individuals after in 
vitro stimulation with either SEA, SWA or anti-IgE. Hista-
mine-releasability in vitro for each infected individual at the 
pre-treatment time point is compared with that 1-day (black 
square) and 21-days (open square) after treatment after in 
vitro stimulation with SEA (Fig 2a), SWA (Fig 2b) and anti-IgE 
(Fig 2c). Any point that plots on the diagonal line is 
unchanged from the pre-treatment level. The differences 
between the levels of histamine-releasability between pre-
treatment and 1-day post-treatment were statistically signifi-
cant for all stimuli. The differences between the levels of his-
tamine-releasability between pre-treatment and 21-days 
post-treatment were statistically significant and nearly signifi-
cant for SEA-stimulated and anti-IgE-stimulated histamine 
release, respectively.
Plasma levels of Ag-specific IgE and IgG4 measured at each time point in the plasma of S.-m soni-infected p opleFigure 3
Plasma levels of Ag-specific IgE and IgG4 measured 
at each time point in the plasma of S.-mansoni-
infected people. Antibody levels measured by ELISA at 
pre-treatment (N = 32), 1 day post-treatment (N = 32) and 
21 days post-treatment (N = 25) are expressed as OD val-
ues. Individual measurements are represented by dots. Medi-
ans are represented by horizontal bars.Page 5 of 12
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tamine was the consequence of the up-regulation of total
cellular histamine content.
At 21-days post-treatment there would have been few, if
any, parasites remaining in the blood, and little or no par-
asite Ag in the circulation [29]. For example, at this time-
point CAA, a diagnostic schistosome gut-associated circu-
lating Ag, could not be detected in the plasma of 98% of
the treated individuals (data not shown). Thus, basophils
present at 21-days post-treatment would not have been
subject to in vivo Ag challenge prior to in vitro culture. In
these circumstances the basophils would have reacted
normally to in vitro Ag stimulation via surface receptor
bound Abs, including IgE. However, the continued reduc-
tion in histamine-releasability 21-days post-treatment,
compared with the infected pre-treatment state, suggests
the presence of a, yet to be identified, infection-associated
priming factor that is removed or becomes ineffective after
treatment.
We examined the possibility that, alternatively, an Ag-spe-
cific desensitisation, comparable to the immuno-thera-
peutic desensitisation of allergic patients, could have
occurred. A role for IL-10 and TNFα of T-cell origin has
been postulated in basophil desensitisation after wasp
venom immunotherapy [30], and these cytokines were
detectable in the plasma at all time-points. We found
however no correlation between the plasma concentra-
tion of these cytokines and histamine-releasability after
treatment in this study cohort (data not shown). The
mechanism down-regulating histamine-releasability at 21
days post-treatment is therefore likely to be different from
the one involved in therapeutic immuno-desensitisation.
Comparison of SEA-, SWA- and anti-IgE-induced 
histamine-releasability
We assumed that anti-IgE would induce the highest possi-
ble IgE-dependent histamine-releasability and compared
it to that of SEA and SWA, to assess the secretagogue
potential of the parasite Ag. As shown in Figure 2, both
SWA and SEA induced significantly higher histamine-
releasability than anti-IgE Ab at all study time-points: SEA
Vs anti-IgE pre-treatment p = 0.002 (n = 32); 1-day post-
treatment p = 0.002 (n = 29), 21-days post-treatment p =
0.004 (n-25); SWA Vs anti-IgE pre-treatment p = 0.004 (n
= 32), 1-day post-treatment p = 0.002 (n = 29), 21-days
post-treatment p = 0.000 (n = 25). There was no statisti-
cally significant difference between histamine-releasabil-
ity induced by SEA and that induced by SWA at pre-
treatment and at 1 day post-treatment, but at 21 days post-
treatment, SWA-induced histamine-releasability was sig-
nificantly higher than SEA-induced histamine-releasabil-
ity (p = 0.005, N = 25). Parasite factors, such as a S.
mansoni analogue to human translationally controlled
tumour protein (TCTP), may induce an additional IgE-
independent histamine release, or enhanced non Ag-spe-
cific, IgE-dependent release [13,31]. These non-classical
pathways could therefore be involved in the additional
histamine-release. However we didn't detect histamine-
release from basophils from non-infected individuals
after SEA or SWA stimulation under the same conditions.
This enhanced histamine-releasability could then appear
to be specifically induced by the experience of infection.
We however have to consider the fact that our methodol-
ogy may have been less sensitive than those used in the
description of these non-classical pathways and that low
levels of histamine-release in non-infected individuals
may not have been detected. Thus, it is possible that par-
asite factors may have directly induced additional or
enhanced histamine-releasability.
Post-treatment changes in in vitro basophil sensitivity to 
anti-IgE and parasite Ags
The sensitivity of blood cells to parasite Ag or anti-IgE
stimulation was assessed by determining the lowest of the
9 concentrations of Ag or of the 3 concentrations of anti-
IgE used in the assay, that was capable of triggering a sig-
nificant histamine-release. The lower the concentration
required, the higher the blood cell sensitivity. At 1-day
post-treatment, the sensitivity of blood cells from most
individuals was either unchanged (anti-IgE:15 out of 32,
SEA:17 out of 32, SWA:12 out of 32) or had decreased
(anti-IgE:13 out of 32, SEA:13 out of 32, SWA:13 out of
32), compared with the number of individuals with
increased sensitivity for each stimuli (SEA p = 0.006, SWA
p = 0.030 or anti-IgE Ab p = 0.026). This reduced sensitiv-
ity was parallel to the decline in histamine-release at 1-day
post-treatment shown in Figure 2. This general decline in
basophil sensitivity during the first 24-hours after treat-
ment contrasted with an increase in sensitivity from 1-day
to 21-days post-treatment. During this period, the sensi-
tivity of blood cells from most individuals increased (anti-
IgE:9 out of 25, SEA:12 out of 25, SWA:13 out of 25) or
was unchanged (anti-IgE:14 out of 25, SEA:9 out of 25,
SWA:8 out of 25) for SEA, SWA or anti-IgE Ab stimulation
(p= 0.021, p = 0.010 and p = 0.024, respectively), mirror-
ing the re-establishment of histamine-release at 21-days
post-treatment shown above. When the changes in sensi-
tivity between consecutive time-points were compared,
significant or highly significant negative associations were
found between the changes from pre-treatment to 1-day
post-treatment and the changes from 1-day to 21-days
post-treatment (r = -0.636, p = 0.001 for anti-IgE; r = -
0.568, p = 0.003 for SEA; r = -0.465, p = 0.019 for SWA; n
= 25, for all conditions). Thus, the individuals whose
basophil sensitivity decreased from pre-treatment to 1-
day post-treatment tended to be the same individuals
whose basophil sensitivity had increased by 21-days post-
treatment.Page 6 of 12
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strength of histamine-release, sensitivity reflects the Ag
concentration required to induce degranulation. In a
mouse experimental model, sensitivity, contrarily to his-
tamine-releasability, was shown to be correlated to affin-
ity of the IgE for the Ag [32]. This reduced sensitivity to Ag
or anti-IgE Ab could reflect qualitative rather than quanti-
tative changes in plasma antibodies. The parallel changes
in histamine-releasability and in basophil sensitivity
show that reduced basophil sensitivity could be partly
responsible for the post-treatment reduction in hista-
mine-releasability in blood culture after treatment.
The lack of relationship between anti-IgE- and Ag-induced 
histamine-releasability, and plasma total IgE, specific IgE 
and specific IgG4
Plasma levels of total IgE, anti-SEA and anti-SWA IgE and
IgG4 were measured at the 3 study time points. Hista-
mine-releasability was not associated with level of total
IgE at any time-point. Indeed, despite a statistically signif-
icant increase in total IgE between pre-treatment and 21-
days post-treatment (p = 0.024, N= 24), anti-IgE stimu-
lated histamine-releasability was lower in the blood of
most patients at 21-days post-treatment. Histamine-
releasability was associated with parasite-specific plasma
IgE levels only for SEA-induced histamine-release with
anti-SEA IgE at 1-day post-treatment (r = 0.513, p = 0.012,
n = 23), when histamine-releasability was at its lowest.
There was no statistically significant change in plasma
anti-SEA IgE between pre-treatment and 1-day post-treat-
ment, as shown in Figure 3, while there was a very signif-
icant decrease in SEA-induced histamine-releasability. No
significant correlation between IgG4 levels and SEA or
SWA Ag-stimulated histamine-releasability was found.
Thus it would appear that post-treatment changes in the
level of histamine-releasability in vitro were regulated
either at the cellular level or by serum factors affecting the
in vivo sensitisation, priming or neutralisation of the
basophils or of other surface-bound factors, other than
ELISA-detectable parasite-specific IgE or IgG4. A similar
lack of relationship between plasma Ab and histamine-
release has been reported from studies of cord-blood
basophils passively-sensitized with plasma from S. man-
soni infected adults [18] and RBL-2H3 cells transfected
with FcεRI sensitized with plasma from allergic patients
[33].
The influence of pre-treatment infection intensity on post-
treatment anti-IgE- and Ag-induced histamine releasability
The intensity of S. mansoni infection pre-treatment,
expressed in eggs per gram of faeces, was compared with
the changes in histamine-releasability pre- and post-treat-
ment. Figure 4 shows that at 1-day post-treatment, the
time when histamine-releasability was lowest, the pre-
treatment intensity of infection correlated negatively with
SEA-, SWA- and anti-IgE-stimulated % histamine-release.
Thus, the greater the intensity of S. mansoni-infection pre-
treatment, the lower the releasability of blood cell
histamine at 1-day post-treatment. This clearly demon-
strates that the decline in histamine-releasability seen
after treatment was dependent on the S. mansoni-infection
rather than on the direct action of the drug itself. As the
degree of 1-day post-treatment suppression of histamine-
releasability was dependent on the intensity of infection,
but is triggered by treatment, this suggests that suppres-
sion of % histamine-release is related to the amount of Ag
that is released in vivo by the drug-induced disruption of
different numbers of infecting parasites. This desensitized
state persists until 21-days post-treatment in relation to
SEA (Figure 2). Interestingly, a negative association
between level of Ag exposure and subsequent reactivity
has been reported in bee-keepers allergic to bee venom, in
whom the number of stings was negatively correlated to
skin sensitivity and who showed less side reaction to
venom desensitisation than other bee venom allergic
patients who have been less exposed to bee stings before
treatment [34].
Although the relationship between infection and low
post-treatment histamine-releasability could result from
an infection intensity-dependent down-regulation mech-
anism there is a particularly interesting alternative expla-
nation. It has been suggested from studies in the murine
model of schistosomiasis that parasite induced histamine-
release may regulate the intensity of schistosome infection
by triggering inflammation reactions that prevent super-
infection [35]. In relation to the present study, it is possi-
ble that a high histamine-releasability response to parasite
Ag might be protective against infection/re-infection. If
this were true, the association between low infection
intensity and high histamine-releasability would result in
a restriction of parasite numbers by an IgE-dependent his-
tamine-release, not intense infection suppressing hista-
mine-release. With regard to this hypothesis, it would be
interesting to test if the magnitude of in vitro histamine-
releasability in response to treatment was predictive of the
subsequent resistance or susceptibility of individuals to
re-infection with S. mansoni.
Conclusions
The present work describes changes in basophils biology
and the modulation of basophil function, induced by the
treatment of S. mansoni infection. Some of these changes
may be a return to steady non-infected state. S. mansoni
treatment-induced human basophil immune modulation
is associated with pre-treatment infection intensity. The
mechanisms involved in post-treatment basophil desensi-
tisation at 1-day post-treatment may have similarities to
those that induce desensitisation to allergens with immu-
notherapy. Analysis of histamine-release from naïvePage 7 of 12
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The relationship between S. mansoni pre-treatment infection intensity and the histamine-releasability from 
the blood of infected individuals, pre- and post-treatment, after stimulation with anti-IgE or schistosome Ag. 
Histamine-relasability (the maximum level of histamine-release, expressed as the % of total cellular histamine content of the 
blood of each individual), from the washed blood cells of S. mansoni-infected individuals after in vitro stimulation with either SEA 
(n = 29), SWA (n = 32) or anti-IgE (n = 32), compared with the pre-treatment levels of S. mansoni-infection (eggs per gramme 
of stool, epg). Statistically significant correlations between epg and histamine-releasability are shown (Spearman's rank 
correlations).Page 8 of 12
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same individuals should provide data on the plasma fac-
tors involved in the regulation of the basophil response. It
is hoped that such studies, coupled to the monitoring of
reinfection after treatment, will provide detailed informa-
tion about the role of basophils in IgE mediated immuno-
logical protection against reinfection after treatment and
mechanisms by which the potential adverse effects of IgE-
mediated immune effector mechanisms are down-regu-
lated.
Methods
Study cohort selection
A cohort of forty individuals was selected in the fishing
village of Bugoigo, on the Eastern Shore of Lake Albert,
Masindi District, Uganda. Vegetation in the shallow parts
of the lake was an ideal habitat for snails of the genus
Biomphalaria, particularly B. sudanica and B. stanleyi, the
two intermediate host species of S. mansoni in this area.
Adult men were, through their occupation, the part of the
population the most exposed to infection. The select study
group comprised males aged between 18 and 45 years old
(mean age 34.5 years), having resided in Bugoigo for at
least three years and consenting to participate. The selec-
tion was made after parasitological examination of three
stool samples per individual, with two Kato thick smears
per sample using 50 mg of faeces per slide [36]. All the
selected individuals had detectable S. mansoni eggs, but
those with over 70 eggs per slide were excluded to reduce
the number of outliers. The mean pre-treatment egg count
for the selected cohort was 282 (range = 983) eggs per
gram of faeces.
Non-infected group
A group of 8 healthy volunteers, members of the sample
collection team, was bled at the same time as the third
bleed of the study group. This control group comprised 5
Africans (2 females and 3 males) and 3 Europeans (1
female and 2 males).
Blood collection and PZQ treatment
Informed consent was obtained from all those who partic-
ipated in this study, in line with the National guidelines
of the Ugandan Ministry of Health, whose ethical review
committees approved all the protocols used, and the US
Department of Health and Human Services. Thirty ml-
blood samples taken by venipuncture in heparinised
syringes (10 U/ml heparin Na salt, Sigma, UK) were col-
lected from the 33 participants before they received a sin-
gle dose of 40 mg/kg body weight of PZQ. The
participants were asked to come back to donate blood
samples a second time (1-day post-treatment) exactly 24
hours after having been treated. A third sample was taken
21-days post-treatment from the 28 participants who
came back to donate blood. Only 3 ml of the collected
blood was used for histamine assays. The rest of the blood
was used for other assays that were parts of the same main
study. At the completion of this study the whole Bugoigo
community was treated with PZQ.
Antigen coating of microtitre plates used for histamine 
release
Glass fibre microtitre plates from Ref Lab, Denmark were
coated with 25 µl of the following substances:
Histamine (50 ng/ml) added to four wells; α-IgE from
DAKO, Denmark, used in three concentrations (1:200 (7
µg/ml), 1:1000, 1:2000), each concentration was added
in two wells; SEA and SWA, used in nine concentrations
with the dilution factor 3.5 and each concentration was
added into two wells. The highest concentration of SEA
and SWA was 50 µg/ml. All dilutions were made in dis-
tilled water containing 5% glycerol. Subsequently the
allergen coated microtitre plates were dried for 6 hours at
37°C, and thereafter the plates were packed and sealed
until use in Bugoigo. Preliminary experiments using
blood from 3 S. mansoni-infected patients showed that
histamine-release performed in Ag-coated plates (stored
for 3 months at 20°C) varied less than 5% from histamine
release induced by freshly prepared Ag. Control experi-
ments using blood from 5 non-infected individuals
showed no histamine-release to SEA and SWA (data not
shown).
Histamine release assay
Histamine-release was performed using the glass fibre
assay described elsewhere [37], which allows the capture
of released histamine, irrespective of basophil source,
after stimulation. The assay was however simplified for
direct release of histamine by peripheral blood without
passive sensitisation. In brief 3 ml of each blood sample
was washed twice in PIPES buffer (Ref Lab, Denmark) at
room temperature to eliminate platelets and plasma fac-
tors not already cell-bound. The samples were reconsti-
tuted to the initial volume with PIPES buffer and
thereafter referred to as "washed blood", with the addi-
tion of IL-3 (5 ng/ml washed blood). Substances in the
Ag-coated plates were dissolved by adding 25 µl PIPES
buffer to each well prior to addition of 25 µl washed
blood per well. Histamine was released and subsequently
bound to glass fibres in the microtitre plate. Thereafter the
plate was washed with distilled water. The plates were
stored in the dark at room temperature during the 21-days
study period in Bugoigo and subsequently shipped to the
Ref Lab for histamine analysis.
Histamine analysis
Histamine was measured by spectrofluorometry as
described elsewhere[37]. Spontaneous release is automat-Page 9 of 12
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data by the analysis software.
Antigen preparation
S. mansoni worms and eggs for Ag preparation were
obtained from mice infected with 250 S. mansoni cercar-
iae. Forty-two days after infection mice were injected s.c.
with hydrocortisone acetate (2.5 mg/mouse), to reduce
granuloma formation around the eggs in the livers. 49-
days post-infection, the portal blood of infected mice
were perfused to recover the worms, as described previ-
ously [38]. Recovered worms were frozen in droplets in
liquid nitrogen and stored in liquid nitrogen until use.
PBS soluble extract of adult worm Ag (SWA) was prepared
by recovering the lipid-free supernatant fraction of the
finely crushed frozen worms after centrifugation for one
hour at 10,000 g at 4°C as described previously [39]. Sol-
uble egg Ag (SEA) was the supernatant fluid obtained after
S. mansoni eggs were homogenised in PBS as described
previously [40] except that the homogenisation step was
done by sonication. Both SWA and SEA were filtered
through sterile 0.22 µm pore-size filters and endotoxin
content was measured using the Limulus Amebocyte
Lysate Kit (QCL-1000, Biowhittaker Inc, Walkersville,
MD, USA). The levels of endotoxin in the native Ag used
in these studies were as follows 10.7 ng endotoxin /mg
SEA and 25 ng endotoxin /mg SWA. Whole blood cultures
in the presence of these levels of endotoxin induced nei-
ther cell activation, nor cytokine release (data not shown).
Specific antibody determination
A semi-quantitative measurement of SEA- and SWA- spe-
cific IgE and IgG4 isotypes was carried out on the plasma
of the study individuals by ELISA as described previously
[7]. Briefly, SEA-specific and SWA-specific antibodies were
captured in Immulon-2 flat bottom plates (Dynex) coated
with SEA and SWA, respectively. Detection of IgG4 and
IgE was done by use of mouse anti-human IgG4 clone RJ4
(Skybio Ltd, UK) and mouse anti-human IgE clone HP
6029 (CN Biosciences, UK), respectivelyThe assays were
developed using biotinylated sheep anti-mouse Ig fol-
lowed by streptavidin-biotin-HRP complex (both reagents
from A P Biotech) and by incubation with O-phenylene-
diamine (OPD). Optical densities (OD) were read at 490
nm. Samples from the 3 time-points were processed at the
simultaneously to allow for comparison of OD.
Total IgE determination
Total IgE were quantified in the plasma of the study indi-
viduals by in-house sandwich ELISA. Both antibodies
were obtained from Pharmingen. Mouse anti-human IgE
clone G7-18 was used for capture in Immulon 2 flat bot-
tom plates (Dynex). Detection was made with bioti-
nylated mouse anti-human IgE clone G7-26, with poly-
HRP (CLB) amplification and incubation with OPD. Sam-
ple plasmas and human IgE myeloma standards (Calbio-
chem) were diluted in 10% animal sera (an equivolume
mix of complement-inactivated sera from mouse, rat, goat
and fetal bovine) to block heterophilic antibodies.
CAA measurement
CAA was quantified in the plasma of the study individuals
by ELISA, after modification of the method described by
Deelder and colleagues [41]. The modification consisted
in using different anti-CAA antibodies as those reported in
the original article. Both capture and detection antibodies
were provided by Dr G.J. van Dam and Prof. A.M. Deelder,
University of Leiden, the Netherlands. In summary,
trichloroacetic acid-treated samples or standards (TCA
soluble SWA) [42] were incubated in Immulon 2 HB
plates (Dynex) coated with mouse anti-CAA antibody
clone 147-39A and captured CAA was detected with bioti-
nylated mouse anti-CAA clone 147-3G4. Incubations with
alkaline phospatase-conjugated streptavidin (Dako) and
the chromogenic substrate pNPP (Sigma) allowed reading
at 405 nm.
Data treatment
For each Ag or anti-IgE Ab stimulus, the amount of hista-
mine released at the stimulus concentration that induced
the highest release was defined as the maximal histamine-
release. The sensitivity was defined as the lowest stimulus
concentration required to induce a histamine-release
equal or greater to 10 ng/ml. This threshold represents 2
standard deviations from the average histamine quantifi-
cation using a blank sample. Statistical analysis with non
parametric tests was done with SPSS 10 for Macintosh:
comparisons of related variables were made using Wil-
conxon's ranks test, independent variables were compared
using Mann-Whitney U test and correlations between var-
iables were made using Spearman's test.
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